| Identification | Back Directory | [Name]
VPC-13566 | [CAS]
218464-59-6 | [Synonyms]
VPC-13566
VPC 13566,VPC13566
VPC-13566 >=98% (HPLC)
2-(7-Methyl-1H-indol-3-yl)quinoline
Quinoline, 2-(7-methyl-1H-indol-3-yl)- | [Molecular Formula]
C18H14N2 | [MDL Number]
MFCD30723190 | [MOL File]
218464-59-6.mol | [Molecular Weight]
258.32 |
| Chemical Properties | Back Directory | [Boiling point ]
490.8±33.0 °C(Predicted) | [density ]
1.225±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 20mg/mL, clear | [form ]
powder | [pka]
15.92±0.30(Predicted) | [color ]
white to beige | [InChIKey]
FPKBNOVQNMJTEJ-UHFFFAOYSA-N | [SMILES]
CC1=CC=CC2=C1NC=C2C3=NC4=CC=CC=C4C=C3 |
| Hazard Information | Back Directory | [Uses]
VPC-13566, a BF3-specific small molecule, is an androgen receptor (AR) inhibitor. VPC-13566 is effective in inhibiting AR transcriptional activity in vitro as well as the growth of AR-dependent PCa cell lines. VPC-13566 can be used as a chemical probe to help identify unknown AR partners.VPC-13566 can be used for the research of cancer. | [Biological Activity]
VPC-13566 is Binding Function 3 (BF3)-specific inhibitor of the androgen receptor. VPC-13566 potently inhibits AR transcriptional activity by displacement of the BAG1L peptide from the BF3 pocket. VPC-13566 inhibits the growth of various prostate cancer cell lines including an enzalutamide-resistant cell line and inhibits the growth of AR-dependent prostate cancer xenograft in mice. | [References]
[1] Lallous N, et al. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation. Mol Cancer Ther. 2016 Dec;15(12):2936-2945. DOI:10.1158/1535-7163.MCT-16-0354 |
|
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|